

Jorg Oddens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5305378/publications.pdf>

Version: 2024-02-01

39
papers

3,121
citations

430874

18
h-index

330143

37
g-index

42
all docs

42
docs citations

42
times ranked

3663
citing authors

#	ARTICLE	IF	CITATIONS
1	Duration of Androgen Suppression in the Treatment of Prostate Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 2516-2527.	27.0	865
2	EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-muscle-invasive Stage Ta T1 Urothelial Bladder Cancer Patients Treated with 3 Years of Maintenance Bacillus Calmette-Guérin. <i>European Urology</i> , 2016, 69, 60-69.	1.9	445
3	Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. <i>European Urology</i> , 2013, 63, 462-472.	1.9	382
4	Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?. <i>European Urology</i> , 2016, 69, 231-244.	1.9	282
5	Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. <i>European Urology</i> , 2014, 65, 69-76.	1.9	254
6	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer: An International Collaborative Multi-stakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
7	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer: an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	1.2	96
8	One Immediate Postoperative Instillation of Chemotherapy in Low Risk Ta, T1 Bladder Cancer Patients. Is it Always Safe?. <i>European Urology</i> , 2004, 46, 336-338.	1.9	94
9	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance-guided Biopsy for Early Risk Restrification in Active Surveillance of Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 165-172.	6.2	83
10	Holmium Laser Lithotripsy for Ureteral Calculi: Predictive Factors for Complications and Success. <i>Journal of Endourology</i> , 2008, 22, 257-260.	2.1	78
11	The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Guérin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911. <i>European Urology</i> , 2014, 66, 694-701.	1.9	68
12	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2013, 48, 152-157.	6.2	63
13	Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. <i>BJU International</i> , 2016, 118, 423-428.	2.5	28
14	Cancer survivors' preference for follow-up care providers: a cross-sectional study from the population-based PROFILES-registry. <i>Acta Oncologica</i> , 2017, 56, 278-287.	1.8	28
15	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	3.1	23
16	Deep Learning-based Recurrence Prediction in Patients with Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2022, 8, 165-172.	3.1	22
17	External Beam Radiation Therapy Followed by Interstitial Radiotherapy with Iridium-192 for Solitary Bladder Tumours: Results of 111 Treated Patients. <i>European Urology</i> , 2009, 56, 113-122.	1.9	20
18	Prostate-sparing cystectomy: long-term oncological results. <i>BJU International</i> , 2009, 104, 1239-1243.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Non-operative treatment for perforated gastro-duodenal peptic ulcer in Duchenne Muscular Dystrophy: a case report. <i>BMC Surgery</i> , 2004, 4, 1.	1.3	16
20	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancerâ€”A Review. <i>Cancers</i> , 2022, 14, 38.	3.7	16
21	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. <i>BMC Cancer</i> , 2019, 19, 1133.	2.6	14
22	Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study. <i>JMIR Research Protocols</i> , 2020, 9, e15687.	1.0	14
23	Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study. <i>BMC Cancer</i> , 2018, 18, 861.	2.6	13
24	Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Nonâ€”Muscle-invasive Stage Taâ€”T1 Urothelial Bladder Cancer Patients Treated with 1â€”3 Years of Maintenance Bacillus Calmette-GuÃ©rin. <i>Eur Urol</i> 2016;69:60â€”9. <i>European Urology</i> , 2016, 69, e123-e124.	1.9	11
25	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-GuÃ©rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020, 203, 283-291.	0.4	10
26	The challenge of prostate biopsy guidance in the era of mpMRI detected lesion: ultrasound-guided versus in-bore biopsy. <i>British Journal of Radiology</i> , 2022, 95, 20210363.	2.2	6
27	The Current State of Predicting Response on Bacillus Calmette-GuÃ©rin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action. <i>European Urology</i> , 2018, 73, 749-750.	1.9	5
28	Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. <i>European Urology Open Science</i> , 2022, 39, 48-54.	0.4	5
29	Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. <i>BJU International</i> , 2022, 130, 611-618.	2.5	5
30	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. <i>BJU International</i> , 2021, 128, 511-518.	2.5	4
31	A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer. <i>Scientific Reports</i> , 2022, 12, 7017.	3.3	4
32	Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722210885.	2.0	3
33	A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice. <i>European Urology Open Science</i> , 2022, 39, 7-13.	0.4	3
34	Type of treatment, symptoms and patient satisfaction play an important role in primary care contact during prostate cancer follow-up: results from the population-based PROFILES registry. <i>BMC Family Practice</i> , 2021, 22, 218.	2.9	2
35	Chemohyperthermia with Mitomycin-C Compared with Bacillus Calmette-GuÃ©rin: A â€œHotâ€”Topic. <i>European Urology</i> , 2016, 69, 1053-1054.	1.9	1
36	The effect of metformin on bladder cancer incidence and outcomes â€”a systematic review and meta-analysis. <i>Bladder Cancer</i> , 2022, , 1-18.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Rare cause of ureteral stenosis more than 10 years after kidney transplantation. <i>Urology</i> , 2005, 65, 798.	1.0	0
38	Case report. Endo-ureterale ballonkatheter bij urinelekkage en ureterstricturen na urinedeviatie volgens Bricker. <i>Tijdschrift Voor Urologie</i> , 2017, 7, 23-26.	0.1	0
39	Recurrence in Non-Muscle Invasive Bladder Cancer Patients: External Validation of the EORTC, CUETO and EAU Risk Tables and Towards a Non-Linear Survival Model. <i>Bladder Cancer</i> , 2020, 6, 277-284.	0.4	0